Speciality: Gastroenterology
Description:
A warm welcome to all the medical professionals in this interesting session on Biologics in gastroenterology.
Biologics have revolutionized the treatment of several gastrointestinal disorders, particularly inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. These advanced therapies target specific molecules in the immune system, such as TNF-alpha or interleukins, which play key roles in the inflammation that drives these conditions. By reducing inflammation at the molecular level, biologics help control symptoms, promote healing of the gut lining, and prevent flare-ups.
In clinical practice, biologics like infliximab, adalimumab, and ustekinumab are used when conventional treatments fail to provide adequate relief. They have significantly improved the quality of life for patients with moderate to severe IBD, offering long-term disease control and reducing the need for surgery. Although biologics are highly effective, they do come with risks, including an increased chance of infections, requiring careful monitoring. As research advances, biologics continue to expand treatment options in gastroenterology, offering hope for patients with difficult-to-manage conditions.
Therefore, get an overall knowledge of Biologics in gastroenterology. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation